The reasons for hepatitis C treatment failure remain unknown but may be related to different
host responses to therapy. In this study, we compared hepatic gene expression in patients …

Background & Aims: Pegylated interferon (IFN)-α plus ribavirin is the most effective treatment
of chronic hepatitis C but has unpleasant side effects and high costs. A large proportion of …

BACKGROUND & AIMS: The therapeutic mechanisms of ribavirin for hepatitis C are unclear.
Microarray analyses have shown that ribavirin increases induction of interferon-stimulated …

Treating chronic hepatitis C virus (HCV) infection using pegylated alpha interferon and
ribavirin leads to sustained clearance of virus and clinical improvement in approximately …

Objective Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in
chronic hepatitis C but the mechanism remains controversial. We studied correlates of …

BACKGROUND & AIMS: The probability of response to peginterferon and ribavirin is
associated with numerous host and virological factors. Attainment of a rapid virological …

This study tested the hypothesis that high‐dose peginterferon alfa‐2a (PEG‐IFNα‐2a) for the
first 12 weeks would increase early and sustained virological response (SVR) rates in …

BACKGROUND & AIMS: Chronic hepatitis C virus (CHC) infection is treated with
interferon/ribavirin, but only a subset of patients respond. Treatment nonresponders have …

Abstract Interferon (IFN)‐α–based therapy for chronic hepatitis C is effective in fewer than
50% of all treated patients, with a substantially lower response rate in black patients. The …

BACKGROUND/AIMS: Prediction of sustained virological response (SVR) during treatment
would allow clinicians to identify patients most likely to benefit from therapy. METHODS …